The FDA’s data on mifepristone can’t be trusted — here’s why
For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.
Original Source
Read the full article at Thehill →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.